Prognostic effect of programmed cell death ligand 1/programmed cell death 1 expression in cancer stem cells of human oral squamous cell carcinoma

被引:1
|
作者
Todoroki, Keita [1 ,2 ]
Abe, Yushi [1 ,2 ]
Matsuo, Katsuhisa [1 ,2 ]
Nomura, Hidetoshi [1 ]
Kawahara, Akihiko [3 ]
Nakamura, Yoshiaki [4 ]
Nakamura, Moriyoshi [1 ]
Seki, Naoko [1 ]
Kusukawa, Jingo [1 ]
机构
[1] Kurume Univ, Dent & Oral Med Ctr, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan
[2] Kouhoukai Med Corp, Takagi Hosp, Dept Dent & Oral Surg, Okawa, Fukuoka 8310016, Japan
[3] Kurume Univ Hosp, Dept Diagnost Pathol, Kurume, Fukuoka 8300011, Japan
[4] Oita Saiseikai Hita Hosp, Dept Dent & Oral Surg, Hita, Oita 8771292, Japan
关键词
CSC; OSCC; CD44v3; CD24; programmed cell death ligand 1; programmed cell death 1; immune checkpoint inhibitors; HEAD; PD-L1; CD24; IDENTIFICATION; IMMUNOTHERAPY; POPULATION; RECURRENT;
D O I
10.3892/ol.2024.14213
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The relationship between cancer stem cells (CSCs) in oral squamous cell carcinoma (OSCC) and programmed cell death ligand 1 (PD-L1)/programmed cell death 1 (PD-1) remains unclear. Therefore, the present study aimed to clarify the association between the CD44v3(high)/CD24(low) immunophenotype of CSCs in OSCC and PD-L1/PD-1 co-expression, and to assess the prognostic effect of CSCs in terms of immune checkpoint molecules. Formalin-fixed, paraffin-embedded tissue samples and clinicopathological data from 168 patients with OSCC were retrospectively retrieved. Immunohistochemical staining and reverse transcription quantitative polymerase chain reaction were applied to a tissue microarray of the invasive front of each case. Semi-automated cell counting was used to assess CD44v3, CD24, PD-L1 and PD-1 expression by immunohistochemistry (IHC) using a digital image analysis program. Associations between immunological markers and clinicopathological variables were estimated. Patients with the CSC immunophenotype CD44v3(high)/CD24(low), and patients with a high PD-L1/PD-1-positive cell density in the tumor parenchyma and stroma had significantly lower survival rates. Furthermore, patients with the CSC immunophenotype (CD44v3(high)/CD24(low)) and high PD-L1/PD-1 co-expression had even lower survival rates (P<0.01, log-rank test). Notably, there was a positive correlation between CD44v3 and PD-L1 expression (tau=0.1096, P=0.0366, Kendall rank correlation coefficient) and a negative correlation between CD24 and PD-1 expression (tau=-0.1387, P=0.0089, Kendall rank correlation coefficient). Additionally, the high CD44v3 expression group, as determined by IHC, exhibited significantly decreased expression of U2 small nuclear RNA auxiliary factor 1 (U2AF1) at the mRNA level compared with that in the low CD44v3 expression group (P<0.001, Mann-Whitney U test), and U2AF1 and PD-L1 mRNA expression exhibited a significant negative correlation (tau=-0.3948, P<0.001, Kendall rank correlation coefficient). In conclusion, CSCs in OSCC may evade host immune mechanisms and maintain CSC stemness via PD-L1/PD-1 co-expression, resulting in unfavorable clinical outcomes.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] PROGNOSTIC VALUE OF PROGRAMMED DEATH LIGAND 1 EXPRESSION IN OVARIAN CLEAR CELL CARCINOMA
    Zhu, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 565 - 565
  • [22] Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Expression in Extranodal NK/T-Cell Lymphoma
    Jung, Ho Young
    Kim, Wook Youn
    Kim, Tae Min
    Heo, Dae Seog
    Kim, Chul-Woo
    Jeon, Yoon Kyung
    MODERN PATHOLOGY, 2015, 28 : 353A - 353A
  • [23] Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Expression in Extranodal NK/T-Cell Lymphoma
    Jung, Ho Young
    Kim, Wook Youn
    Kim, Tae Min
    Heo, Due Seog
    Kim, Chul-Woo
    Jeon, Yoon Kyung
    LABORATORY INVESTIGATION, 2015, 95 : 353A - 353A
  • [24] Programmed cell death 1 ligand 1 signals in cancer cells
    Kornepati, Anand V. R.
    Vadlamudi, Ratna K.
    Curie, TylerJ
    NATURE REVIEWS CANCER, 2022, 22 (03) : 174 - 189
  • [25] Programmed Cell Death-Ligand 1 (PD-L1) Expression in Oral Cavity Squamous Cell Carcinoma (OSCC)
    Satgunaseelan, Laveniya
    Madore, Jason
    Chia, Noel
    Lum, Trina
    Palme, Carsten E.
    Boyer, Michael
    Scolyer, Richard A.
    Clark, Jonathan R.
    Gupta, Ruta
    LABORATORY INVESTIGATION, 2016, 96 : 329A - 329A
  • [26] Programmed Cell Death-Ligand 1 (PD-L1) Expression in Oral Cavity Squamous Cell Carcinoma (OSCC)
    Satgunaseelan, Laveniya
    Madore, Jason
    Chia, Noel
    Lum, Trina
    Palme, Carsten E.
    Boyer, Michael
    Scolyer, Richard A.
    Clark, Jonathan R.
    Gupta, Ruta
    MODERN PATHOLOGY, 2016, 29 : 329A - 329A
  • [27] Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma
    Yokoyama, Shintaro
    Miyoshi, Hiroaki
    Nakashima, Kazutaka
    Shimono, Joji
    Hashiguchi, Toshihiro
    Mitsuoka, Masahiro
    Takamori, Shinzo
    Akagi, Yoshito
    Ohshima, Koichi
    CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4727 - 4734
  • [28] miRNA-A and programmed death ligand 1 (PD-L1) expression in oral squamous cell carcinoma
    Hyung, Hong
    Ko, Yoon Ho
    Jin, Lee Hee
    Jeon, Sang Hoon
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [29] Candida albicans induces upregulation of programmed death ligand 1 in oral squamous cell carcinoma
    Wang, Xu
    Zhao, Weiwei
    Zhang, Wenqing
    Wu, Shuangshuang
    Yan, Zhimin
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2022, 51 (05) : 444 - 453
  • [30] Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer
    Enkhbat, Tumenjin
    Nishi, Masaaki
    Takasu, Chie
    Yoshikawa, Kozo
    Jun, Higashijima
    Tokunaga, Takuya
    Kashihara, Hideya
    Ishikawa, Daichi
    Shimada, Mitsuo
    ANTICANCER RESEARCH, 2018, 38 (06) : 3367 - 3373